{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:04:11Z","timestamp":1778047451224,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Pharmaceuticals K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40744-023-00539-z","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T08:27:43Z","timestamp":1676795263000},"page":"615-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-3539","authenticated-orcid":false,"given":"Masahiko","family":"Miyashiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"key":"539_CR1","doi-asserted-by":"crossref","unstructured":"Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1\u2013ITC16.","DOI":"10.7326\/AITC201901010"},{"issue":"6","key":"539_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","volume":"30","author":"M Kojima","year":"2020","unstructured":"Kojima M, Nakayama T, Tsutani K, et al. Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol. 2020;30(6):941\u20137.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"539_CR3","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis. 2020;23(12):1676\u201384.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"539_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"539_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679\u2013707.","journal-title":"Clin Ther"},{"issue":"2","key":"539_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"539_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"539_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet"},{"issue":"12","key":"539_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","volume":"16","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017;16(12):1185\u201395.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"539_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","volume":"47","author":"JA Karlsson","year":"2008","unstructured":"Karlsson JA, Kristensen LE, Kapetanovic MC, G\u00fclfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47(4):507\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"539_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford). 2007;46(7):1191\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"539_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/rheumatology\/keq169","volume":"49","author":"S Lloyd","year":"2010","unstructured":"Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2010;49(12):2313\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"539_CR13","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar3249","volume":"13","author":"R Rendas-Baum","year":"2011","unstructured":"Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors. Arthritis Res Ther. 2011;13(1):R25.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"539_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/14397595.2020.1797283","volume":"31","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: real-world evidence from post-hoc analysis of post-marketing surveillance data. Mod Rheumatol. 2021;31(3):566\u201374.","journal-title":"Mod Rheumatol"},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","volume":"10","author":"J Mahlich","year":"2016","unstructured":"Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence. 2016;10:1509\u201319.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"539_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901\u201313.","journal-title":"Clin Ther"},{"issue":"1","key":"539_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13561-014-0032-4","volume":"4","author":"S Neubauer","year":"2014","unstructured":"Neubauer S, Cifaldi M, Mittendorf T, Ganguli A, Wolff M, Zeidler J. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Heal Econ Rev. 2014;4(1):32.","journal-title":"Heal Econ Rev"},{"issue":"8","key":"539_CR18","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1185\/03007990802229548","volume":"24","author":"E Wu","year":"2008","unstructured":"Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229\u201340.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"539_CR19","first-page":"728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728\u201340.","journal-title":"J Manag Care Pharm"},{"issue":"11","key":"539_CR20","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"539_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40744-018-0095-5","volume":"5","author":"M Okazaki","year":"2018","unstructured":"Okazaki M, Kobayashi H, Ishii Y, Kanbori M, Yajima T. Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients. Rheumatol Ther. 2018;5(1):185\u2013201.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"539_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/14397595.2017.1404731","volume":"28","author":"T Takeuchi","year":"2018","unstructured":"Takeuchi T, Harigai M, Tanaka Y, et al. Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: final results of the GO-MONO trial through week 120. Mod Rheumatol. 2018;28(5):770\u20139.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"539_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/14397595.2015.1109762","volume":"26","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Harigai M, Takeuchi T, et al. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. Mod Rheumatol. 2016;26(4):481\u201390.","journal-title":"Mod Rheumatol"},{"key":"539_CR24","doi-asserted-by":"crossref","unstructured":"Mutoh T, Nagai T, Shirai T, Okazaki S, Sato H, Fujii H. Predictive factors for retention of golimumab over a median 4-year duration in Japanese patients with rheumatoid arthritis in a real-world setting: a retrospective study and literature review. Int J Rheumatic Dis. 2022;25(3):335\u201343.","DOI":"10.1111\/1756-185X.14281"},{"issue":"7","key":"539_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"539_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/14397595.2020.1797266","volume":"31","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: results from a Japanese post-marketing surveillance study. Mod Rheumatol. 2021;31(3):556\u201365.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"539_CR27","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1007\/s00296-011-2312-1","volume":"32","author":"SK Cho","year":"2012","unstructured":"Cho SK, Sung YK, Choi CB, Bae SC. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012;32(12):3851\u20136.","journal-title":"Rheumatol Int"},{"issue":"8","key":"539_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3899\/jrheum.130901","volume":"41","author":"H Matsubara","year":"2014","unstructured":"Matsubara H, Kojima T, Kaneko A, et al. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy. J Rheumatol. 2014;41(8):1583\u20139.","journal-title":"J Rheumatol"},{"issue":"9","key":"539_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","volume":"29","author":"JH Kang","year":"2014","unstructured":"Kang JH, Park DJ, Lee JW, et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014;29(9):1205\u201311.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"539_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40744-018-0101-y","volume":"5","author":"M Okazaki","year":"2018","unstructured":"Okazaki M, Kobayashi H, Shimizu H, Ishii Y, Yajima T, Kanbori M. Safety, effectiveness, and treatment persistence of golimumab in elderly patients with rheumatoid arthritis in real-world clinical practice in Japan. Rheumatol Ther. 2018;5(1):135\u201348.","journal-title":"Rheumatol Ther"},{"key":"539_CR31","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"539_CR32","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/annrheumdis-2013-203435","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Kay J, Matteson EL, et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014;73(10):1811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"539_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/ard.2006.068304","volume":"66","author":"DE Furst","year":"2007","unstructured":"Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66(7):893\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"539_CR34","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis. 2014;73(12):2174\u20137.","journal-title":"Ann Rheum Dis"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13075-015-0841-9","volume":"17","author":"ME Weinblatt","year":"2015","unstructured":"Weinblatt ME, Fleischmann R, van Vollenhoven RF, et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther. 2015;17:325.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"539_CR36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172\u201380.","journal-title":"JAMA"},{"issue":"9","key":"539_CR37","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"539_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40744-014-0002-7","volume":"1","author":"MJ Bergman","year":"2014","unstructured":"Bergman MJ, Elkin EP, Ogale S, Kamath T, Hamburger MI. Response to biologic disease-modifying anti-rheumatic drugs after discontinuation of anti-tumor necrosis factor alpha agents for rheumatoid arthritis. Rheumatol Ther. 2014;1(1):21\u201330.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"539_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","volume":"74","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015;74(2):430\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"539_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/14397595.2016.1206242","volume":"27","author":"H Matsuno","year":"2017","unstructured":"Matsuno H, Katayama K. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. Mod Rheumatol. 2017;27(2):246\u201351.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"539_CR41","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s10067-016-3227-8","volume":"35","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Kondo H, Takeuchi T. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35(11):2829\u201334.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"539_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/25785826.2018.1542942","volume":"41","author":"M Umeda","year":"2018","unstructured":"Umeda M, Koga T, Ichinose K, et al. Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. Immunol Med. 2018;41(4):181\u20136.","journal-title":"Immunol Med"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00539-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00539-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00539-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T18:08:34Z","timestamp":1682618914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00539-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,18]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00539-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,18]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}